1554458-53-5

Basic information

• Product Name: BAY-1217389
• Synonyms: BAY-1217389
• CAS NO: 1554458-53-5
• Molecular Formula: C27H24F5N5O3
• Molecular Weight: 561.503176
• Mol File: 1554458-53-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BAY-1217389(CAS DataBase Reference)
• NIST Chemistry Reference: BAY-1217389(1554458-53-5)
• EPA Substance Registry System: BAY-1217389(1554458-53-5)

Safety Data

• Hazardous Substances Data: 1554458-53-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
BAY-1217389 is used as an antitumor agent for its ability to inhibit monopolar spindle 1, a key enzyme involved in cell division. By targeting this enzyme, BAY-1217389 demonstrates potential in treating various types of cancer by disrupting the uncontrolled cell division characteristic of malignant cells.
Used in Cancer Research:
In the field of cancer research, BAY-1217389 serves as a valuable tool for studying the role of monopolar spindle 1 in cancer cell division and the potential of targeting this enzyme for therapeutic intervention. BAY-1217389 can help researchers better understand the molecular mechanisms underlying cancer progression and identify new strategies for cancer treatment.
Used in Drug Development:
BAY-1217389 is utilized in the development of novel cancer therapeutics, as its mechanism of action offers a unique approach to targeting cancer cells. By inhibiting monopolar spindle 1, BAY-1217389 has the potential to be developed into a new class of antitumor drugs, providing an alternative treatment option for patients with various types of cancer.

Upstream product

• 1206487-36-6 6,8-dibromoimidazo[1,2-b]pyridazine 
• 1263425-59-7 8-bromo-6-chloro-3-iodoimidazo[1,2-b]pyridazine 
• 933190-51-3 8-bromo-6-chloro-imidazo[1,2-b]pyridazine 
• 261763-29-5 2,3-difluoro-4-methoxy-phenol 
• 1365243-95-3 4-{6-bromo-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-b]pyridazin-3-yl}-N-cyclopropyl-2-methylbenzamide 
• 1365243-78-2 [4-(cyclopropylcarbamoyl)-3-methylphenyl]boronic acid 
• 345965-99-3 4-bromo-N-cyclopropyl-2-methylbenzamide 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 1365243-96-4 6-bromo-3-iodo-N-(3,3,3-trifluoropropyl)imidazo[1,2-b]pyridazin-8-amine 
• 1351374-48-5 N-cyclopropyl-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 1365243-73-7 6,8-dibromo-3-iodoimidazo[1,2-b]pyridazine 

Relevant articles and documents

SUBSTITUTED IMIDAZOPYRIDAZINES

The present invention relates to substituted imidazopyridazine compounds, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

COMBINATIONS FOR THE TREATMENT OF CANCER

The present invention relates to combinations of at least two compounds A and B, compound A being an inhibitor of Mps-1 kinase, and compound B being an inhibitor of an anti-apoptotic protein of the Bcl-2 family. Another aspect of the present invention relates to the use of such combinations as described supra for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of cancer. Another aspect of the present invention relates to the use of an anti- apoptotic protein from the Bcl-2 family as a sensitizer of cells to Mps-1 inhibitors. Another aspect of the present invention relates to the use of the ratio of pro-apoptotic and anti-apoptotic proteins from the Bcl-2 family in a biological sample as a biomarker for a Mps-1 kinase inhibitor treatment.

COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER

The present invention relates to a combination comprising an Mps-1 kinase inhibitor and a mitotic inhibitor. The present invention also relates to the use of said combination for the treatment of cancer, in particular of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer.